Skip to content

Study · Animal study (in vivo) · rat · 2021

3 results

Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.

Glazova NY, Manchenko DM, Volodina MA, Merchieva SA, Andreeva LA, Kudrin VS, Myasoedov NF, Levitskaya NG

Neuropeptides28 Dec 2020Cited by 1 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to fluvoxamine as pups, Semax reduced anxiety-like behaviour.

    In plain wordsIn rats exposed to an antidepressant as pups, Semax reduced anxiety-like behaviour.

    Peptide
    Semax
    Outcome
    DecreaseAnxiety-like behaviour after neonatal fluvoxamine exposure
    Study

    ratn: not reported in source

    neonatal fluvoxamine (FA) exposure model
    Comparator
    Vehicle
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · postnatal days 15-28As given in this study (rat).

    Source sentences

    Summary
    Semax administration reduced the anxiety-like behaviour, improved learning abilities and normalized the levels of brain biogenic amines impaired by the FA exposure.
    1 context sentence
    Summary · context
    Rat pups received FA or vehicle injections on postnatal days 1-14, a time period equivalent to 27-40 weeks of human foetal age. After FA treatment, rats were administered with Semax or vehicle on postnatal days 15-28.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to fluvoxamine as pups, Semax improved learning abilities.

    In plain wordsIn rats exposed to an antidepressant as pups, Semax improved learning ability.

    Peptide
    Semax
    Outcome
    IncreaseLearning abilities after neonatal fluvoxamine exposure
    Study

    ratn: not reported in source

    neonatal fluvoxamine (FA) exposure model
    Comparator
    Vehicle
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · postnatal days 15-28As given in this study (rat).

    Source sentences

    Summary
    Semax administration reduced the anxiety-like behaviour, improved learning abilities and normalized the levels of brain biogenic amines impaired by the FA exposure.
    1 context sentence
    Summary · context
    Rat pups received FA or vehicle injections on postnatal days 1-14, a time period equivalent to 27-40 weeks of human foetal age. After FA treatment, rats were administered with Semax or vehicle on postnatal days 15-28.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to fluvoxamine as pups, Semax normalized brain biogenic amine levels that were impaired by fluvoxamine.

    In plain wordsIn rats exposed to an antidepressant as pups, Semax returned disturbed brain monoamine levels toward normal.

    Peptide
    Semax
    Outcome
    MixedBrain biogenic amine levels after neonatal fluvoxamine exposure
    Study

    ratn: not reported in source

    neonatal fluvoxamine (FA) exposure model
    Comparator
    Vehicle
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · postnatal days 15-28As given in this study (rat).

    Source sentences

    Summary
    Semax administration reduced the anxiety-like behaviour, improved learning abilities and normalized the levels of brain biogenic amines impaired by the FA exposure.
    1 context sentence
    Summary · context
    Rat pups received FA or vehicle injections on postnatal days 1-14, a time period equivalent to 27-40 weeks of human foetal age. After FA treatment, rats were administered with Semax or vehicle on postnatal days 15-28.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.